Skip to main content
. 2015 Aug 28;6(31):31659–31673. doi: 10.18632/oncotarget.5229

Figure 4. Effects of activin B on SMAD2 and SMAD3 phosphorylation in endometrial cancer cells.

Figure 4

A., HEC-1B and KLE cells were treated without (Ctrl) or with 50 ng/mL activin B (Act B) for 30 or 60 min and Western blot was used to measure the levels of phosphorylated SMAD2 (p-SMAD2) and SMAD3 (p-SMAD3) in relation to their total levels (SMAD2 and SMAD3, respectively). B., HEC-1B and KLE cells were pre-treated with vehicle control (DMSO) or SB431542 (10 μM) for 1 h and then treated with 50 ng/mL activin B for 60 min. SMAD2 and SMAD3 phosphorylation was examined by Western blot.